Tirzepatide
Dual GIP / GLP-1 receptor agonist
Related Laboratory Supplies
Essential items for laboratory research and sample preparation.
Third-Party Tested
HPLC Purity & Mass Spec Identity
Batch-Specific COA
Certificate for Each Batch
Discreet Packaging
Plain, Unbranded & Tamper-Evident
Same-Day Dispatch
Order Before 2PM AEST, Australia-Wide
Tirzepatide is a synthetic peptide with dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist activity. It is studied for its involvement in metabolic signalling, incretin pathways and receptor interactions.
Tirzepatide Australia research material described on this page is intended strictly for laboratory research. It is not supplied for human or veterinary use.
What Is Tirzepatide?
Tirzepatide is a synthetic, modified 39-amino-acid peptide classified as a dual GIP and GLP-1 receptor agonist. It interacts with two incretin receptors involved in glucose-related signalling and metabolic regulation.
Researchers study Tirzepatide to understand how these receptor pathways function individually and together. Its molecular structure includes a fatty-acid-containing side chain that influences its pharmacological properties.
Tirzepatide is also the active ingredient in approved prescription medicines. However, independently supplied Tirzepatide research peptide material is separate from those pharmaceutical products. Its identity, purity and suitability for a particular laboratory application must be assessed using the documentation for the supplied batch.
Tirzepatide in Metabolic Research
Tirzepatide has been investigated in laboratory, preclinical and clinical research involving metabolic function.
Research areas include glucose-related signalling, incretin receptor interactions, cellular responses and regulation of metabolic pathways. Experimental models can help researchers examine how dual-receptor activation influences signalling mechanisms.
Published clinical studies provide information about the pharmaceutical compound in humans. These findings should not be interpreted as evidence of the safety, efficacy or suitability of independently supplied laboratory material.
Results from cell-based experiments, animal models and clinical studies must be considered within their respective research settings.
Quick Product Information
| Specification | Details |
|---|---|
| Product name | Tirzepatide |
| Research classification | Synthetic dual incretin receptor agonist |
| Research targets | GIP receptor (GIPR), GLP-1 receptor (GLP-1R) |
| Molecular formula | C₂₂₅H₃₄₈N₄₈O₆₈ |
| Molecular weight | Approximately 4,813.45 g/mol |
| CAS number | 2023788-19-2 |
| Physical form | Lyophilised powder (freeze-dried) |
| Available strengths | 10mg, 15mg, 30mg, 45mg and 60mg |
| Purity | Refer to verified batch-specific results |
| Analytical testing | HPLC and MS/LC-MS, where documented |
| Certificate of Analysis | Batch-specific CoA documenting analytical testing methods, identity verification and purity results, where available. |
| Storage requirements | Store according to batch-specific guidelines. Protect from moisture, light and temperature fluctuations. Refer to the product documentation for verified storage conditions. |
| Intended use | Laboratory and in-vitro research only |
How Tirzepatide Works in Research
GIP Receptor Activity
Glucose-dependent insulinotropic polypeptide is an incretin hormone involved in metabolic signalling. Tirzepatide activates GIP receptors, allowing researchers to examine receptor-mediated responses and downstream cellular pathways.
GIP receptor investigations commonly focus on cyclic AMP (cAMP) signalling and interactions between incretin pathways.
GLP-1 Receptor Activity
Glucagon-like peptide-1 receptors participate in glucose-dependent signalling and other metabolic processes. Tirzepatide also activates these receptors, providing a model for investigating GLP-1-related cellular responses.
Studies examine receptor activation, intracellular signalling and differences between individual incretin pathways.
Dual-Receptor Agonism
Tirzepatide’s activity at both GIP and GLP-1 receptors makes it relevant to research examining combined incretin signalling. Responses depend on the experimental model, receptor expression and study conditions.
Tirzepatide vs Other Incretin Research Peptides
Tirzepatide, Semaglutide and Retatrutide differ in their receptor activity.
| Compound | Receptor activity |
|---|---|
| Semaglutide | GLP-1 |
| Tirzepatide | GIP + GLP-1 |
| Retatrutide | GIP + GLP-1 + Glucagon |
Semaglutide targets the GLP-1 receptor, while Tirzepatide acts at both GIP and GLP-1 receptors. Retatrutide additionally activates the glucagon receptor.
These differences are relevant when selecting receptor pathways for experimental investigation. They do not establish the suitability of any particular research material for a given study.
Tirzepatide Research in Australia
Australian laboratories working with Tirzepatide should consider material identification, batch traceability, supporting analytical documentation and applicable regulatory requirements.
Tirzepatide is an active ingredient in TGA-approved prescription medicines in Australia. Independently supplied research material must not be represented as equivalent to those approved products.
The Therapeutic Goods Administration (TGA) regulates therapeutic goods, while other requirements may apply to laboratory chemicals and research activities.
Researchers should assess the intended application and relevant Australian regulatory obligations before using the material.
Specifications
Certificate of Analysis
Quality, Purity and Batch Testing
Analytical testing helps laboratories assess the identity and composition of Tirzepatide research material.
High-Performance Liquid Chromatography (HPLC) can separate components and support an assessment of chromatographic purity. Mass Spectrometry (MS), including LC-MS, can provide molecular mass information relevant to identity verification.
A batch-specific Certificate of Analysis (CoA) should identify the tested material, batch reference, analytical methods and reported results.
Purity values should only be stated when supported by verified testing documentation.
Analytical purity does not establish sterility, biological safety or suitability for human administration. Testing results must be interpreted within the scope of the methods used.
Storage & Handling
Storage and Laboratory Handling
Tirzepatide research material should be stored according to the conditions specified in its product and batch documentation.
Laboratory handling should consider temperature exposure, moisture, light sensitivity where applicable, container integrity and contamination prevention.
Vials should remain clearly identified, and handling procedures should follow established laboratory standard operating procedures.
Storage temperatures, expiry periods and stability after reconstitution should not be assumed without supporting product-specific data.
Research Use Only: For Research Use Only. Not for human or veterinary use. This material is intended strictly for laboratory and in-vitro research purposes and must not be consumed or administered.
Reconstitution calculator: Tirzepatide 15mg
Work out concentration and the volume to draw for each aliquot before you add diluent.
- Concentration
- –
- Volume per aliquot
- –
- On a 1 mL (U-100) syringe
- –
- Aliquots per vial
- –
A laboratory arithmetic aid only. Verify every calculation independently. Not dosing guidance; research use only.
Tirzepatide Frequently Asked Questions
Tirzepatide is a synthetic peptide that activates GIP and GLP-1 receptors. It has been investigated in metabolic research involving incretin signalling, glucose regulation and receptor-mediated cellular responses.
Tirzepatide is a modified 39-amino-acid peptide classified as a dual incretin receptor agonist. Its structure includes a fatty-acid-containing modification that influences its pharmacological characteristics.
Tirzepatide targets the glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Both are G protein-coupled receptors involved in metabolic and cellular signalling pathways.
Semaglutide acts as a GLP-1 receptor agonist. Tirzepatide activates both GIP and GLP-1 receptors, allowing researchers to investigate signalling involving two incretin receptor pathways.
Tirzepatide has dual GIP and GLP-1 receptor activity. Retatrutide additionally targets the glucagon receptor, making it a triple-receptor agonist with a different pharmacological profile.
Researchers investigate Tirzepatide to understand incretin receptor interactions, glucose-dependent signalling and cellular metabolic responses. Its dual-receptor activity provides a model for examining interconnected signalling pathways.
Tirzepatide has the molecular formula C₂₂₅H₃₄₈N₄₈O₆₈ and a molecular weight of approximately 4,813.45 g/mol. These values describe the parent compound rather than every possible salt formulation.
HPLC can assess chromatographic purity by separating sample components. Mass spectrometry supports molecular identity assessment. The reported results depend on the analytical methods and tested batch.
A CoA should identify the material, batch number, testing methods, analytical results and relevant specifications. It should also provide sufficient information to trace the reported findings.
No. This independently supplied Tirzepatide material is designated for laboratory and in-vitro research only. It is not an approved medicine and must not be consumed or administered.
Tirzepatide is the active ingredient in Mounjaro. However, independently supplied Tirzepatide research material is not Mounjaro and does not carry the pharmaceutical product's TGA approval.
No. This product is supplied strictly for in-vitro laboratory research. It is not approved for human or veterinary use and must not be consumed or administered.
Orders placed before 2PM AEST on business days are dispatched the same day from Melbourne. Standard Post takes 3–7 business days and Express Post 1–3 business days, both tracked and discreet.



Reviews
There are no reviews yet.